PRESS RELEASE – SpinChip Diagnostics ASA secures NOK 145 million in private placement

Oslo, Norway, [22] March 2024 — SpinChip Diagnostics ASA (“SpinChip”), a pioneering diagnostics company developing a next-generation point-of-care platform for in vitro diagnostics, today announcedV the completion of its financing round, successfully securing NOK 145 million in the form of a private placement. The financing round was led by bioMérieux, a world leader in the field of in vitro diagnostics, with its NOK 115 million investment.

The proceeds from the financing round will be used to further advance SpinChip’s proprietary point-of care (POC) in vitro diagnostics platform, prepare for a CE mark in 2025, and for general corporate purposes.

ABG Sundal Collier and Carnegie Investment Bank acted as joint bookrunners (the “Joint Bookrunners”) for the financing round, while Wiersholm acted as legal advisor to the company and AGP Advokater acted as legal advisor to the Joint Bookrunners.

Contact information:

Morten Jurs, Chief Executive Officer
E-mail: mj@spinchip.no
Phone: +47 991 67 922

Hamed Brodersen, Chief Financial Officer
E-mail: hb@spinchip.no
Phone: +47 404 68 110

About SpinChip Diagnostics ASA

Representing the future of point-of-care testing, SpinChip Diagnostics was founded in Norway in 2012. SpinChip’s proprietary platform is focused on in vitro diagnostics (IVD) to develop diagnostic tests for acute and chronic cardiac indications where test results are rapidly needed to provide patients with lifesaving treatments. The all-in-one platform is based on unique microfluidic technology in combination with nanotechnology-based ultrasensitive detection, which together can relay test results as accurately as high-sensitive laboratory diagnostic machines within minutes, from only a fraction of a droplet of blood. Visit www.spinchip.no for more information